Get started
Author

Elisabetta Fenu

Observed names: E Fenu, E. Fenu, Fenu, Elisabetta
ORCID: 0000-0001-7666-3319
Observed ORCID: 0000-0001-7666-3319
OpenAlex ID: A5085700120
Clinical assessment and management of multimorbidity: summary of NICE guidance
2016 · Caroline Farmer, Elisabetta Fenu, et al. · BMJ · 260
Rehabilitation after stroke: summary of NICE guidance
2013 · K. Dworzynski, G. Ritchie, et al. · BMJ · 80
Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance
2012 · L.-Y. Chong, E. Fenu, et al. · BMJ · 77
Cry for health: a quantitative evaluation of a hospital-based advocacy intervention for domestic violence and abuse
2019 · Gemma Halliwell, Sandi Dheensa, et al. · BMC Health Services Research · 48
PDF
National Clinical Guideline Centre Cost-Effectiveness Assessment for the National Institute for Health and Clinical Excellence
2011 · David Wonderling, Laura Sawyer, et al. · Annals of Internal Medicine · 39
Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer
2012 · V Harding, E Fenu, et al. · British Journal of Cancer · 34
PDF
Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom
2015 · Sarah L. Bermingham, Ralph Hughes, et al. · Value in Health · 26
Management of stable angina: summary of NICE guidance
2011 · N. O. Flynn, A. Timmis, et al. · BMJ · 26
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
2022 · Elisabetta Fenu, Vasily Lukyanov, et al. · PharmacoEconomics - Open · 15
PDF
Sedation of children in the emergency department for short painful procedures compared with theatre, how much does it save? Economic evaluation
2010 · A. Boyle, V. Dixon, et al. · Emergency Medicine Journal · 14
Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective
2024 · Bob G. Schultz, Camille N. Kotton, et al. · Journal of Medical Virology · 12
Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis
2017 · Dalia Dawoud, Elisabetta Fenu, et al. · Value in Health · 9
PDF
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France
2022 · Mark Oppe, Bogdan Muresan, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 8
EE571 Cost-Effectiveness of Maribavir for Post-Transplant Refractory Cytomegalovirus Infection With or Without Resistance: A UK Perspective
2022 · E Chowdhury, T de Lacey, et al. · Value in Health · 6
Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK
2019 · Grant McCarthy, Elisabetta Fenu, et al. · Advances in Therapy · 6
Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s disease
2024 · Chitra Karki, Gary Hantsbarger, et al. · BMC Gastroenterology · 2
PDF
Network Meta-Analysis of Randomized Trials in Relapsed/Refractory Multiple Myeloma: Relative Efficacy for Patients Who Are Lenalidomide-Refractory
2023 · Efstathios Kastritis, Rebecca Harvey, et al. · Blood · 2
Basal Insulin Regimens: Systematic Review, Network Meta-Analysis, and Cost - Utility Analysis for the National Institute For Health and Care Excellence (Nice) Clinical Guideline on Type 1 Diabetes Mellitus in Adults
2015 · D Dawoud, E Fenu, et al. · Value in Health · 2
EE231 Cost-Effectiveness Model of Ranolazine for Treating Chronic Stable Angina Patients From Kingdom of Saudi Arabia Perspective
2025 · Rashmika Sharma, Minal Jain, et al. · Value in Health
CO247 The Relationship Between Surrogate Endpoints and Overall Survival in Myelofibrosis Clinical Trials: Results From a Targeted Literature Review
2025 · Louise Linsell, Yuxian Chen, et al. · Value in Health
RWD130 Elacestrant vs Everolimus + Exemestane in Patients With ER+/HER2- ESR1-Mutated Advanced/Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy + CDK4/6 Inhibitor ≥12 Months: Combining Real-World and Clinical Trial Data
2024 · F. Felizzi, E. Fenu, et al. · Value in Health
DOP57 Predictive modelling to examine long term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s Disease
2021 · M Maruszczak, K Genenz, et al. · Journal of Crohn s and Colitis
Intravenous Fluids for Children: Cost and Threshold Analysis to Inform the National Institute for Health and Care Excellence (NICE) Clinical Guideline Recommendation
2016 · D Dawoud, E Fenu, et al. · Value in Health
S37– GRADE imprecision Criteria: Interpretation and impact on the NICE Lower Urinary Tract Symptoms in Men Guideline
2010 · Lee‐Yee Chong, Clare Jones, et al. · Otolaryngology
PDF
S36– Experiences presenting GRADE to the Guideline Development Group on the NICE Lower Urinary Tract Symptoms (LUTS) Guideline
2010 · Clare N. Jones, Lee‐Yee Chong, et al. · Otolaryngology
Works count: 28
Citation count: 666
H-index: 11
I10-index: 11
Year
Topic
Type